The FDA has approved FluMist Quadrivalent,from Medimmune a vaccine to prevent seasonal influenza in people ages 2 years through 49...
AstraZeneca confirmed that the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has...
Potential to be the first and only self-administered flu vaccine; AstraZeneca’s Supplemental Biologics License Application (sBLA) for the approval of a self- or caregiver-administered option for FluMist Quadrivalent, a needle-free nasal spray, has been accepted for review by the FDA
AstraZeneca announced that the European Commission (EC) has on 6 December 2013 granted Marketing Authorisation to Fluenz Tetra. Fluenz Tetra...
AstraZeneca has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
The FDA has approved Fluarix Quadrivalent Influenza Virus Vaccine from Glaxo Smith Kline, for the immunisation of children (three years...
Glaxo Smith Kline has recalled doses of its FluLaval Quadrivalent flu vaccine due to effectiveness problems. GSK has announced that...
The FDA has approved its quadrivalent formulation of Flublok influenza vaccine, from Protein Sciences Corporation. Flublok Quadrivalent protects against 4...
Protein Sciences Corporation announced topline data showing that Flublok Quadrivalent � the quadrivalent version of FDA-approved trivalent Flublok influenza vaccine...
GlaxoSmithKline announced that the FDA has approved FluLaval Quadrivalent influenza Virus Vaccine for the active immunization of persons three years...